Three families of CD4-induced antibodies are associated with the capacity of plasma from people living with HIV to mediate ADCC in presence of CD4-mimetics - Tauzin, Alexandra; Marchitto, Lorie; Bélanger, Étienne; Benlarbi, Mehdi; Beaudoin-Bussières, Guillaume; Prévost, Jérémie; Yang, Derek; Chiu, Ta-Jung; Chen, Hung-Ching; Bourassa, Catherine; Medjahed, Halima; Korzeniowski, Marek K; et al. (medRxiv, 2024)
CD4-mimetics (CD4mcs) are small molecule compounds that mimic the interaction of the CD4 receptor with HIV-1 envelope glycoproteins (Env). Env from primary viruses normally samples a “closed” conformation which occludes epitopes recognized by CD4-induced (CD4i) non-neutralizing antibodies (nnAbs). CD4mcs induce conformational changes on Env resulting in the exposure of these otherwise inaccessible epitopes. Here we evaluated the capacity of plasma from a cohort of 50 people living with HIV to recognize HIV-1-infected cells and eliminate them by antibody-dependent cellular cytotoxicity (ADCC) in the presence of a potent indoline CD4mc. We observed a marked heterogeneity among plasma samples. By measuring the levels of different families of CD4i Abs, we found that the levels of anti-cluster A, anti-coreceptor binding site and anti-gp41 cluster I antibodies are responsible for plasma-mediated ADCC in presence of CD4mc.IMPORTANCE There are several reasons that make it difficult to target the HIV reservoir. One of them, is the capacity of infected cells to prevent the recognition of HIV-1 envelope glycoproteins (Env) by commonly-elicited antibodies in people living with HIV. Small CD4-mimetic compounds expose otherwise occluded Env epitopes, thus enabling their recognition by non-neutralizing antibodies. A better understanding of the contribution of these antibodies to eliminate infected cells in presence of CD4mc could lead to the development of therapeutic cure strategies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by grants from the National Institutes of Health to A.F. (R01 AI148379, R01 AI150322, AI176531); A.F. and M.P., (R01 AI129769, AI174908). Support for this work was also provided by the NIAID-funded ERASE HIV consortium (UM1 AI-164562) to A.B.S. and A.F., by a CIHR Team Grant #422148, a project grant #451304 and a Canada Foundation for Innovation grant #41027 to A.F. A.F. was supported by a Canada Research Chair on Retroviral Entry #RCHS0235 950-232424. M.B. and G.B-B. are the recipients of CIHR doctoral fellowship. E.B. is a recipient of a CIHR master fellowships. J.P. was the recipients of a CIHR doctoral fellowship. A.T. was supported by a MITACs Elevation post-doctoral fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All work was conducted in accordance with the Declaration of Helsinki in terms of informed consent and approval by an appropriate institutional board. Blood samples were obtained from donors who consented to participate in this research project at Centre Hospitalier de l Universite de Montreal (CHUM). The study was approved by the Institutional Review Board of Centre de Recherche du CHUM (MP-02-2024-11734).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript